MX2022004910A - Metodos de tratamiento de los sintomas del trastorno del espectro autista. - Google Patents
Metodos de tratamiento de los sintomas del trastorno del espectro autista.Info
- Publication number
- MX2022004910A MX2022004910A MX2022004910A MX2022004910A MX2022004910A MX 2022004910 A MX2022004910 A MX 2022004910A MX 2022004910 A MX2022004910 A MX 2022004910A MX 2022004910 A MX2022004910 A MX 2022004910A MX 2022004910 A MX2022004910 A MX 2022004910A
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- methods
- symptoms
- autism spectrum
- spectrum disorder
- Prior art date
Links
- 208000029560 autism spectrum disease Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 208000024891 symptom Diseases 0.000 title abstract 2
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
En la presente se proporcionan métodos de tratamiento de los síntomas asociados con el trastorno del espectro autista (TEA) mediante la administración de una cantidad terapéuticamente eficaz de un triptán.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962925023P | 2019-10-23 | 2019-10-23 | |
US202063011715P | 2020-04-17 | 2020-04-17 | |
PCT/US2020/057133 WO2021081376A1 (en) | 2019-10-23 | 2020-10-23 | Methods of treating the symptoms of autism spectrum disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022004910A true MX2022004910A (es) | 2022-08-18 |
Family
ID=75620321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022004910A MX2022004910A (es) | 2019-10-23 | 2020-10-23 | Metodos de tratamiento de los sintomas del trastorno del espectro autista. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220387396A1 (es) |
EP (1) | EP4048249A4 (es) |
JP (1) | JP2022554090A (es) |
KR (1) | KR20220122602A (es) |
CN (1) | CN114901270A (es) |
AU (1) | AU2020370479A1 (es) |
CA (1) | CA3158781A1 (es) |
IL (1) | IL292367A (es) |
MX (1) | MX2022004910A (es) |
WO (1) | WO2021081376A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4208161A1 (en) * | 2020-10-16 | 2023-07-12 | Purposeful, Ike | Compositions and uses thereof |
JP2024512069A (ja) * | 2021-03-25 | 2024-03-18 | マップライト セラピューティクス,インコーポレイテッド | ゾルミトリプタンを含む医薬組成物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8236787B2 (en) * | 2008-12-09 | 2012-08-07 | Synthonics, Inc. | Frequency modulated drug delivery (FMDD) |
ES2967976T3 (es) * | 2014-05-19 | 2024-05-06 | Univ Northeastern | Compuestos dirigidos a receptor de serotonina |
CN113546174A (zh) * | 2015-02-25 | 2021-10-26 | 加利福尼亚大学董事会 | 用于治疗病症的5ht激动剂 |
CN108243608A (zh) * | 2015-05-22 | 2018-07-03 | 亚利桑那大学董事会 | 用于治疗自闭症谱系障碍及相关症状的方法 |
-
2020
- 2020-10-23 IL IL292367A patent/IL292367A/en unknown
- 2020-10-23 US US17/770,535 patent/US20220387396A1/en active Pending
- 2020-10-23 AU AU2020370479A patent/AU2020370479A1/en active Pending
- 2020-10-23 JP JP2022523272A patent/JP2022554090A/ja active Pending
- 2020-10-23 CA CA3158781A patent/CA3158781A1/en active Pending
- 2020-10-23 WO PCT/US2020/057133 patent/WO2021081376A1/en unknown
- 2020-10-23 KR KR1020227017060A patent/KR20220122602A/ko active Search and Examination
- 2020-10-23 MX MX2022004910A patent/MX2022004910A/es unknown
- 2020-10-23 CN CN202080087440.9A patent/CN114901270A/zh active Pending
- 2020-10-23 EP EP20879266.3A patent/EP4048249A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4048249A1 (en) | 2022-08-31 |
CA3158781A1 (en) | 2021-04-29 |
IL292367A (en) | 2022-06-01 |
US20220387396A1 (en) | 2022-12-08 |
JP2022554090A (ja) | 2022-12-28 |
EP4048249A4 (en) | 2023-12-13 |
KR20220122602A (ko) | 2022-09-02 |
CN114901270A (zh) | 2022-08-12 |
WO2021081376A1 (en) | 2021-04-29 |
AU2020370479A1 (en) | 2022-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022001189A1 (es) | Anticuerpos para cd40. (divisional de solicitud n° 2017003427) | |
MX2022001778A (es) | Metodos para tratar esquizofrenia. | |
EP4302835A3 (en) | Methods of treating ovarian cancer | |
EA202090510A1 (ru) | Способ лечения бокового амиотрофического склероза придопидином | |
MX2022001863A (es) | Metodos para tratar los tumores del estroma gastrointestinal. | |
NZ710444A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
MX2019004500A (es) | Terapia de combinación para la inhibición de componente de complemeto (c3). | |
MX2022004910A (es) | Metodos de tratamiento de los sintomas del trastorno del espectro autista. | |
JOP20210233A1 (ar) | علاجات مركبة وتطابق المريض مع الأجسام ثنائية النوعية المضادة لـ EGFR/c-Met. | |
PH12021550102A1 (en) | Cardiosafe antidiabetic therapy | |
TN2019000210A1 (en) | Antitumoral compounds | |
MX2020008195A (es) | Compuestos para el tratamiento del dolor. | |
MX2023008839A (es) | Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales. | |
CO2021017688A2 (es) | Anticuerpo biespecífico contra α-syn/igf1r y uso del mismo | |
MX2020003243A (es) | Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. | |
ZA202105101B (en) | Peptides for treatment and prevention of diabetes and associated disorders | |
EP3934641A4 (en) | FORMULATIONS FOR THE TREATMENT OF SYMPTOMS OF GROUPS ASSOCIATED WITH AUTISM SPECTRUM DISORDER | |
MY195123A (en) | Potassium Channel Modulators | |
WO2021041716A3 (en) | Therapeutic editing to treat cardiomyopathy | |
GEP20237554B (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
MX2019002149A (es) | Metodo para el tratamiento de prurito y/o comezon. | |
MX2018001684A (es) | Metodo de curacion de heridas. | |
JOP20210216A1 (ar) | علاج السرطان | |
MX2020012292A (es) | Compuestos para el tratamiento de cáncer de pancreas. | |
MX2023003924A (es) | Metodos de administracion de tratamiento antifibrotico. |